DE19709877A1 - 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate - Google Patents

1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate

Info

Publication number
DE19709877A1
DE19709877A1 DE19709877A DE19709877A DE19709877A1 DE 19709877 A1 DE19709877 A1 DE 19709877A1 DE 19709877 A DE19709877 A DE 19709877A DE 19709877 A DE19709877 A DE 19709877A DE 19709877 A1 DE19709877 A1 DE 19709877A1
Authority
DE
Germany
Prior art keywords
chain
carbon atoms
straight
formula
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19709877A
Other languages
German (de)
English (en)
Inventor
Helmut Dr Haning
Ulrich Dr Niewoehner
Ulrich Dr Rosentreter
Thomas Dr Schenke
Joerg Dr Keldenich
Erwin Dr Bischoff
Karl-Heinz Dr Schlemmer
Helmuth Dr Schuetz
Guenter Dr Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE19709877A priority Critical patent/DE19709877A1/de
Priority to HK00107378.7A priority patent/HK1028035B/xx
Priority to PCT/EP1998/001086 priority patent/WO1998040384A1/de
Priority to DK98913595T priority patent/DK0973774T3/da
Priority to ES98913595T priority patent/ES2191294T3/es
Priority to AU68240/98A priority patent/AU727615B2/en
Priority to KR1019997008213A priority patent/KR20000076124A/ko
Priority to AT98913595T priority patent/ATE231509T1/de
Priority to NZ337724A priority patent/NZ337724A/xx
Priority to RU99121518/04A priority patent/RU2219180C2/ru
Priority to JP53913598A priority patent/JP2001514638A/ja
Priority to CA002283211A priority patent/CA2283211A1/en
Priority to BR9807995-6A priority patent/BR9807995A/pt
Priority to HU0001805A priority patent/HUP0001805A3/hu
Priority to EP98913595A priority patent/EP0973774B1/de
Priority to US09/367,538 priority patent/US6174884B1/en
Priority to CNB988049872A priority patent/CN1151155C/zh
Priority to DE59807011T priority patent/DE59807011D1/de
Priority to IL13145098A priority patent/IL131450A0/xx
Publication of DE19709877A1 publication Critical patent/DE19709877A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19709877A 1997-03-11 1997-03-11 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate Withdrawn DE19709877A1 (de)

Priority Applications (19)

Application Number Priority Date Filing Date Title
DE19709877A DE19709877A1 (de) 1997-03-11 1997-03-11 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
HK00107378.7A HK1028035B (en) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinone-derivatives
PCT/EP1998/001086 WO1998040384A1 (de) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
DK98913595T DK0973774T3 (da) 1997-03-11 1998-02-26 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivater
ES98913595T ES2191294T3 (es) 1997-03-11 1998-02-26 Derivados de 1,5-dihidro-pirazolo(3,4-d)-pirimidinona.
AU68240/98A AU727615B2 (en) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo(3,4-d)-pyrimidinone derivatives
KR1019997008213A KR20000076124A (ko) 1997-03-11 1998-02-26 1,5-디히드로-피라졸로[3,4-d]-피리미디논 유도체
AT98913595T ATE231509T1 (de) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo 3,4-d)-pyrimidinon-derivate
NZ337724A NZ337724A (en) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinone derivatives in particular for the treatment of cardiovascular and cerebrovascular diseases, diseases of the peripheral vessels and diseases of the urogenital system
RU99121518/04A RU2219180C2 (ru) 1997-03-11 1998-02-26 Производные 1,5-дигидропиразоло[3,4-d]-пиримидинона
JP53913598A JP2001514638A (ja) 1997-03-11 1998-02-26 1,5−ジヒドロピラゾロ[3,4−d]ピリミジノン誘導体類
CA002283211A CA2283211A1 (en) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinone derivatives
BR9807995-6A BR9807995A (pt) 1997-03-11 1998-02-26 Derivados de 1,5-diidro-pirazol(3,4-d)-pirimidinona
HU0001805A HUP0001805A3 (en) 1997-03-11 1998-02-26 6-benzyl-1,5-dihydro-pyrazolo[3,4-d]-pyrimidin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
EP98913595A EP0973774B1 (de) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinon-derivate
US09/367,538 US6174884B1 (en) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives
CNB988049872A CN1151155C (zh) 1997-03-11 1998-02-26 1,5-二氢-吡唑并[3,4-d]-嘧啶酮衍生物
DE59807011T DE59807011D1 (de) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinon-derivate
IL13145098A IL131450A0 (en) 1997-03-11 1998-02-26 1,5-Dihydro-pyrazolo [3,4-d]-pyrimidinone derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19709877A DE19709877A1 (de) 1997-03-11 1997-03-11 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate

Publications (1)

Publication Number Publication Date
DE19709877A1 true DE19709877A1 (de) 1998-09-17

Family

ID=7822900

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19709877A Withdrawn DE19709877A1 (de) 1997-03-11 1997-03-11 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
DE59807011T Expired - Fee Related DE59807011D1 (de) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinon-derivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59807011T Expired - Fee Related DE59807011D1 (de) 1997-03-11 1998-02-26 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinon-derivate

Country Status (17)

Country Link
US (1) US6174884B1 (cg-RX-API-DMAC7.html)
EP (1) EP0973774B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001514638A (cg-RX-API-DMAC7.html)
KR (1) KR20000076124A (cg-RX-API-DMAC7.html)
CN (1) CN1151155C (cg-RX-API-DMAC7.html)
AT (1) ATE231509T1 (cg-RX-API-DMAC7.html)
AU (1) AU727615B2 (cg-RX-API-DMAC7.html)
BR (1) BR9807995A (cg-RX-API-DMAC7.html)
CA (1) CA2283211A1 (cg-RX-API-DMAC7.html)
DE (2) DE19709877A1 (cg-RX-API-DMAC7.html)
DK (1) DK0973774T3 (cg-RX-API-DMAC7.html)
ES (1) ES2191294T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0001805A3 (cg-RX-API-DMAC7.html)
IL (1) IL131450A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ337724A (cg-RX-API-DMAC7.html)
RU (1) RU2219180C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998040384A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
EP1307201B1 (de) 2000-08-01 2004-11-24 Bayer HealthCare AG Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
BR0115995A (pt) * 2000-12-19 2004-01-13 Merck Patent Gmbh Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
CZ20032350A3 (en) * 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
CN100397023C (zh) * 2003-01-04 2008-06-25 胡云北 黄磷废渣载热量及反应尾气发热量的回收与综合利用方法
HRP20050848A2 (en) * 2003-03-04 2006-06-30 Altana Pharma Ag Purin-6-one-derivatives
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
WO2005021037A1 (en) * 2003-08-28 2005-03-10 Altana Pharma Ag Composition comprising a pulmonary surfactant and a pde2 inhibitor
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
KR100844864B1 (ko) * 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
CN101397299B (zh) * 2007-09-29 2011-11-16 温州大学 一种吡唑[3,4-d]嘧啶酮的合成方法
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
BR112016022519A8 (pt) 2014-04-01 2018-03-06 Pfizer cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
EP3291817B1 (en) * 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
DK3310784T3 (da) 2015-06-17 2020-11-09 Pfizer Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
KR102148587B1 (ko) 2016-02-23 2020-08-26 화이자 인코포레이티드 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
PL3478679T3 (pl) 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
US10633382B2 (en) * 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
JP2020523309A (ja) 2017-06-08 2020-08-06 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ピラゾロピリミジンpde9インヒビター
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
EP3768669B1 (en) 2018-03-23 2023-01-25 Pfizer Inc. Piperazine azaspiro derivaves
USD1029414S1 (en) * 2021-01-19 2024-05-28 Averia Electronics, Inc. Wearable light emitting module with a removable band
USD1021287S1 (en) * 2021-01-19 2024-04-02 Averia Electronics, Inc. Wearable light emitting module with a removable band
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
AU2024413926A1 (en) 2023-12-29 2026-07-09 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3165520A (en) * 1965-01-12 Certificate of correction
US3211732A (en) 1965-10-12 Pyrazolob:x-d]pyrlil/hdines
DE1153023B (de) 1960-05-11 1963-08-22 Ciba Geigy Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3,4-d] pyrimidinen
CH398626A (de) * 1960-05-11 1966-03-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
CH633297A5 (de) 1977-09-16 1982-11-30 Sandoz Ag Verfahren zur herstellung von fluorenphosphoniten.
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
CA2133346A1 (en) * 1992-04-21 1993-10-28 Shri Niwas 7-disubstituted-methyl-4-oxo-3h,5h-pyrrolo[3,2-d]pyrimidine and pharmaceutical uses and compositions containing the same
JPH11501926A (ja) 1995-03-10 1999-02-16 サノフィ ファーマシューティカルズ インコーポレイティド 6−アリールピラゾロ[3,4−d]ピリミジン−4−オン、並びにその組成物及び使用法
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof

Also Published As

Publication number Publication date
WO1998040384A1 (de) 1998-09-17
EP0973774A1 (de) 2000-01-26
HUP0001805A3 (en) 2002-09-30
HUP0001805A2 (hu) 2000-11-28
RU2219180C2 (ru) 2003-12-20
BR9807995A (pt) 2000-03-08
US6174884B1 (en) 2001-01-16
AU727615B2 (en) 2000-12-14
HK1028035A1 (en) 2001-02-02
EP0973774B1 (de) 2003-01-22
DE59807011D1 (de) 2003-02-27
ES2191294T3 (es) 2003-09-01
CA2283211A1 (en) 1998-09-17
NZ337724A (en) 2000-08-25
KR20000076124A (ko) 2000-12-26
DK0973774T3 (da) 2003-05-05
JP2001514638A (ja) 2001-09-11
IL131450A0 (en) 2001-01-28
AU6824098A (en) 1998-09-29
CN1255133A (zh) 2000-05-31
CN1151155C (zh) 2004-05-26
ATE231509T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
EP0973774B1 (de) 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinon-derivate
EP1107968B1 (de) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-on
DE69723447T2 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
DE60034239T2 (de) Aromatische stickstoffhaltige sechs-ring-verbindungen
DE60106252T2 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
EP0944631B1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
DE69816608T2 (de) 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
DE19834047A1 (de) Substituierte Pyrazolderivate
EP1119566A1 (de) Neue heterocyclyl-methyl-substituierte pyrazole
DE19541264A1 (de) Purin-6-on-derivate
EP0275888A2 (de) Neue tricyclische Benzimidazole, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
DE19501482A1 (de) 2,9-disubstituierte Purin-6-one
EP0271040A2 (de) Neue Pyrrolobenzimidazole, Verfahren zu ihrer Herstellung, sowie Arzneimittel
DE2820938A1 (de) Neue imidazoazine und imidazodiazine
DD253823A5 (de) Verfahren zur herstellung neuartiger thienopyridone
DE3533331A1 (de) Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD255344A5 (de) Heteroaryl-oxy-beta-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
WO1993006100A1 (de) NEUE β-CARBOLINDERIVATE, DEREN HERSTELLUNG UND VERWENDUNG IN ARZNEIMITTELN
EP0378850B1 (de) Neue substituierte Pyrido(2,3-d)pyrimidine
DE19709126A1 (de) Arylamin-, -oxy-, -thio-substituierte Dihydropurinone und Pyrazolopyrimidine
DE3780015T2 (de) Kondensierte heterocyclische tetrahydroaminochinolinole und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
EP0519291B1 (de) Aminomethyl-substituierte 2,3-Dihydropyrano(2,3-b)pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4027592A1 (de) Neue pyrrolobenzimidazole, imidazobenzoxazinone und imidazochinolone, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen
WO1998032755A1 (de) Purindione als phosphodiesterasehemmer
DE69614102T2 (de) Pyrazol[1,5-a]pyrimidin derivate

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee